Meeting
2023 ASCO Genitourinary Cancers Symposium
Phase Ib trial of enzalutamide (Enza) with venetoclax (Ven) in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Stuthi Perimbeti
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Stuthi Perimbeti , Anmbreen Jamroze , Kristopher Attwood , Bailey Farmer , Jan Hendrik Beumer , Robert Bies , Ellis Glenn Levine , Jason Kirk , Dean Tang , Gurkamal S. Chatta , Dharmesh Gopalakrishnan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03751436
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 182)
DOI
10.1200/JCO.2023.41.6_suppl.182
Abstract #
182
Poster Bd #
F19
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dharmesh Gopalakrishnan
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew Leonard Laccetti
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
First Author: Vincenzo Gennusa
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.
First Author: Christos Kyriakopoulos